Document is current

Article History

Accepted: 5 September 2022

First Online: 9 September 2022

Declarations

:

: The authors declare no competing interests.

: The study was approved by the Human Research Ethics Committee of the University of Cincinnati. The procedures used in this study adhere to the tenets of the 1964 Declaration of Helsinki.

: NA.

: NA.

: The authors declare that they have no conflict of interest related to the research covered in this article. Jack Shen, Gregory Kuhlman and Andrew have nothing to declare. Luca Marsili has received honoraria from the International Association of Parkinsonism and Related Disorders (IAPRD) Society for social media and web support. Alok Dwivedi is supported as a co-investigator by the NIH (1 R21 HL143030-01) and (R21 AI133207) grants. He is also currently serv- ing as a statistician in CPRIT-funded studies (PP200006, PP190058, PP180003, and PP170068). Dr. Dwivedi is also an Adjunct Associate Professor in the Department of Neurology and Rehabilitation Medicine, University of Cincinnati. Alberto J. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Adamas, Acadia, Acorda, Kyowa Kirin, Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Acadia, and Sunovion. Dr. Espay is cofounder of REGAIN Therapeutics, owner of a provisional patent on compositions and methods for treatment and/or prophylaxis of proteinopathies. Abhimanyu Mahajan has received funding from the Dystonia Medical Research Foundation, the Sunflower Parkinson’s Disease Foundation and the Parkinson’s Foundation, outside of the submitted effort.